非肌层浸润性膀胱肿瘤复发的研究进展
Research Progress on the Recurrence of Non-Muscle Invasive Bladder Tumors
DOI: 10.12677/ACM.2024.141171, PDF,   
作者: 钟 亮：延安大学医学院，陕西 延安；高继学*：延安大学附属医院泌尿外科，陕西 延安
关键词: 非肌层浸润性膀胱肿瘤；复发；Non-Muscle Invasive Bladder Tumor； Recurrence
摘要: 非肌层浸润性膀胱肿瘤(NMIBC)具有较高的发病率和复发率；给患者带来了极大的不适和经济负担。我们对NMIBC的复发进行了PubMed文献检索，本文综述的重点是综合我们目前对与NMIBC复发的相关研究，简要总结了有关性别、分子生物学、生活因素、临床研究、复发机制这五个方面与NMIBC复发的相关研究进展并作一综述。
Abstract: Non-muscle invasive bladder tumor (NMIBC) has a high incidence and recurrence rate. It imposes significant discomfort and economic burden on patients. We conducted a comprehensive literature search on PubMed regarding the recurrence of NMIBC. The focus of this review is to synthesize our current studies on the recurrence patterns observed in NMIBC. This paper provides a concise sum-mary of research progress in five key areas related to NMIBC relapse: gender differences, molecular biology aspects, lifestyle factors influencing recurrence rates, clinical research findings, and under-lying mechanisms contributing to relapse.
文章引用：钟亮, 高继学. 非肌层浸润性膀胱肿瘤复发的研究进展[J]. 临床医学进展, 2024, 14(1): 1182-1187. https://doi.org/10.12677/ACM.2024.141171

参考文献

[1] van Hoogstraten, L.M.C., Vrieling, A., van der Heijden, A.G., et al. (2023) Global Trends in the Epidemiology of Blad-der Cancer: Challenges for Public Health and Clinical Practice. Nature Reviews Clinical Oncology, 20, 287-304. [Google Scholar] [CrossRef] [PubMed]
[2] van Rhijn, B.W.G., Hentschel, A.E., Bründl, J., et al. (2021) Prognostic Value of the WHO 1973 and WHO 2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-Muscle-Invasive Bladder Cancer: A Multicenter European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 4, 182-191. [Google Scholar] [CrossRef] [PubMed]
[3] Flaig, T.W., et al. (2022) NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 20, 866-878.
[4] Robert-son, A.G., Groeneveld, C.S., Jordan, B., et al. (2020) Identification of Differential Tumor Subtypes of T1 Bladder Can-cer. European Urology, 78, 533-537. [Google Scholar] [CrossRef] [PubMed]
[5] Lee, L.J., Kwon, C.S., Forsythe, A., et al. (2020) Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews. ClinicoEconomics and Outcomes Research: CEOR, 12, 693-709. [Google Scholar] [CrossRef] 
[6] Kocan, H. and Kadihasanoglu, M. (2021) Age and Sex Do Not Affect First Year Recurrence in Patients with Non-Muscle Invasive Bladder Cancer. Folia Medica, 63, 242-246. [Google Scholar] [CrossRef] [PubMed]
[7] Uhlig, A., Strauss, A., Seif Amir Hosseini, A., et al. (2018) Gen-der-Specific Differences in Recurrence of Non-Muscle- Invasive Bladder Cancer: A Systematic Review and Me-ta-Analysis. European Urology Focus, 4, 924-936. [Google Scholar] [CrossRef] [PubMed]
[8] Bilski, K., Kozikowski, M., Skrzypczyk, M.A., et al. (2022) Sex Remains Negative Prognostic Factor in Contemporary Cohort of High-Risk Non-Muscle-Invasive Bladder Cancer. Can-cers, 14, 6110. [Google Scholar] [CrossRef] [PubMed]
[9] Gordon, N.S., Humayun-Zakaria, N., Goel, A., et al. (2022) STAG2 Protein Expression in Non-Muscle-Invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes. European Urology Open Science, 38, 88-95. [Google Scholar] [CrossRef] [PubMed]
[10] Toren, P., Brisson, H., Simonyan, D., et al. (2021) Androgen Receptor and Immune Cell PD-L1 Expression in Bladder Tumors Predicts Disease Recurrence and Survival. World Journal of Urology, 39, 1549-1558. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, Y., Wang, G., Cui, T. and Lv, L. (2021) Adhesion GPR123 Is an Indicator for Recurrence and Prognosis in Bladder Cancer. Genes & Genomics, 43, 1317-1325. [Google Scholar] [CrossRef] [PubMed]
[12] Juracek, J., Stanik, M., Vesela, P., et al. (2019) Tumor Expres-sion of miR-34a-3p Is an Independent Predictor of Recurrence in Non-Muscle-Invasive Bladder Cancer and Promising Additional Factor to Improve Predictive Value of EORTC Nomogram. Urologic Oncology: Seminars and Original In-vestigations, 37, 184.e1-184.e7. [Google Scholar] [CrossRef] [PubMed]
[13] Muzaail, H.H., El-Assmy, A., Harraz, A.M., et al. (2022) Pre-diction of Recurrence of Non-Muscle Invasive Bladder Cancer: The Role of Androgen Receptor and miRNA-2909. Urologic Oncology: Seminars and Original Investigations, 40, 197.e25-197.e35. [Google Scholar] [CrossRef] [PubMed]
[14] Besançon, M., Gris, T., Joncas, F.H., et al. (2022) Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. European Urology Open Science, 43, 35-44. [Google Scholar] [CrossRef] [PubMed]
[15] van Zutphen, M., Beeren, I., Aben, K.K.H., et al. (2023) Body Mass Index and Waist Circumference in Relation to Risk of Recurrence and Progression after Non-Muscle Invasive Bladder Cancer. Cancer Medicine, 12, 20459-20469. [Google Scholar] [CrossRef] [PubMed]
[16] Tzelves, L., Katsimperis, S., Bellos, T., et al. (2023) Anthropometric Char-acteristics and Relationship with Non-Muscle Invasive Bladder Cancer in Greece: A Case-Control Study. Archivio Ital-iano Di Urologia E Andrologia, 95, Article 11266. [Google Scholar] [CrossRef] [PubMed]
[17] Matulewicz, R.S., Ravvaz, K., Weissert, J.A., et al. (2021) Association of Smoking Status and Recurrence of Non-Muscle Invasive Bladder Cancer among Patients Managed with Blue Light Cystoscopy. Urologic Oncology: Seminars and Original Investiga-tions, 39, 833.e19-833.e26. [Google Scholar] [CrossRef] [PubMed]
[18] Kwan, M.L., Haque, R., Young-Wolff, K.C., et al. (2022) Smoking Behaviors and Prognosis in Patients with Non- Muscle-Invasive Bladder Cancer in the Be-Well Study. JAMA Network Open, 5, e2244430. [Google Scholar] [CrossRef] [PubMed]
[19] Zuniga, K.B., Graff, R.E., Feiger, D.B., et al. (2020) Lifestyle and Non-Muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Fu-ture Directions. Bladder Cancer, 6, 9-23. [Google Scholar] [CrossRef] 
[20] van Zutphen, M., Hof, J.P., Aben, K.K.H., et al. (2023) Adherence to Lifestyle Recommendations after Non-Muscle Invasive Bladder Cancer Diagnosis and Risk of Recurrence. The American Journal of Clinical Nutrition, 117, 681-690. [Google Scholar] [CrossRef] [PubMed]
[21] Baba, Y., Kikuchi, E., Shigeta, K., et al. (2021) Effects of Tran-surethral Resection under General Anesthesia on Tumor Recurrence in Non-Muscle Invasive Bladder Cancer. Interna-tional Journal of Clinical Oncology, 26, 2094-2103. [Google Scholar] [CrossRef] [PubMed]
[22] Erikson, M.S., Petersen, A.C., Andersen, K.K., et al. (2020) Do Repeated Transurethral Procedures under General Anesthesia Influence Mortality in Patients with Non-Invasive Urothe-lial Bladder Cancer? A Danish National Cohort Study. Scandinavian Journal of Urology, 54, 281-289. [Google Scholar] [CrossRef] [PubMed]
[23] Fukuhara, H., Yamamoto, S., Lai, H.W., et al. (2022) Re-al-World Experience with 5-Aminolevulinic Acid for Photodynamic Diagnosis of Bladder Cancer (2nd Report): Reduced Bladder Recurrence after PDD-TURBT. Photodiagnosis and Photodynamic Therapy, 38, Article 102757. [Google Scholar] [CrossRef] [PubMed]
[24] Teoh, J.Y.-C., Kamat, A.M., Black, P.C., et al. (2022) Recur-rence Mechanisms of Non-Muscle-Invasive Bladder Cancer—A Clinical Perspective. Nature Reviews Urology, 19, 280-294. [Google Scholar] [CrossRef] [PubMed]
[25] Galesloot, T.E., Grotenhuis, A.J., Kolev, D., et al. (2022) Genome-Wide Meta-Analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer. European Urology Oncology, 5, 70-83. [Google Scholar] [CrossRef] [PubMed]

为你推荐